Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AHRQ Comparative Study Agenda Should Emphasize Lit Reviews – McClellan

Executive Summary

The federal government's investment in comparative effectiveness research for drugs should emphasize literature reviews and other alternatives to clinical trials, Centers for Medicare & Medicaid Services Administrator Mark McClellan said

You may also be interested in...



AHRQ Drug Effectiveness Comparisons Will Focus On 10 “Priority Conditions”

Prescription drug comparative effectiveness research will proceed for 10 "priority conditions," thanks to $15 mil. provided by the fiscal year 2005 omnibus appropriations bill, the Agency for Healthcare Research & Quality said Dec. 15

AHRQ Drug Effectiveness Comparisons Will Focus On 10 “Priority Conditions”

Prescription drug comparative effectiveness research will proceed for 10 "priority conditions," thanks to $15 mil. provided by the fiscal year 2005 omnibus appropriations bill, the Agency for Healthcare Research & Quality said Dec. 15

CMS Suggests “Pay For Performance” Approach To Cancer Drug Coverage

The ideal approach to cancer drug reimbursement would tie payment to patient outcomes, Centers for Medicare & Medicaid Services Administrator Mark McClellan said June 15 at a Manhattan Institute luncheon in New York

Related Content

UsernamePublicRestriction

Register

PS044054

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel